Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in High-risk CLL Patients on BTKi
NCT07819214Phase 2Not yet recruiting
- Sponsor
- University of California, Irvine
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in chronic lymphocytic leukemia (CLL), sponsored by University of California, Irvine. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07819214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819214.